Management of Breakthrough Bleeding in Depo‑Provera (DMPA) Users

First‑Line NSAID Therapy

NSAIDs are the preferred initial treatment for breakthrough bleeding in DMPA users; they should be taken for 5–7 days during each bleeding episode. 1, 2
Small randomized trials demonstrated that a 5‑day course of valdecoxib or mefenamic acid achieved significant cessation of bleeding within 7 days compared with placebo, providing Level B evidence for efficacy. 1
NSAIDs act by reducing prostaglandin‑mediated endometrial bleeding and are considered safe for all DMPA users. 1

A 10–20 day course of low‑dose combined oral contraceptives during a bleeding episode effectively stops breakthrough bleeding. 1, 2
When COCs are used, a 24/4 regimen (24 active days / 4 placebo days) is preferred over the traditional 21/7 schedule because it provides greater ovulation suppression and lower rates of breakthrough bleeding. 3

Ethinyl estradiol administered for 10–20 days reduces bleeding more than placebo, although discontinuation rates are high and safety outcomes have not been fully evaluated; evidence is limited. 1
Use of estrogen‑only therapy requires prior medical eligibility screening to rule out contraindications. 1, 2

Contraindication	Source
Positive antiphospholipid antibodies	1
Severe uncontrolled hypertension	5
Ongoing hepatic dysfunction	5
Complicated valvular heart disease	3
Migraines with aura	3
History of thromboembolism or thrombophilia	3
Active smoking in women ≥ 35 years	3

Reassure patients that irregular bleeding is a common and generally harmless side effect of DMPA use. 1, 6
Unscheduled bleeding typically improves with continued DMPA use, and amenorrhea becomes common after ≥ 1 year of therapy. 1
Providing enhanced counseling about expected bleeding patterns has been shown in clinical trials to reduce DMPA discontinuation rates. 1, 6